USFDA completes inspection at Lupin’s global pharmacovigilance group

27 Mar 2023 Evaluate

United States Food and Drug Administration (USFDA) has completed a Post-marketing Adverse Drug Experience (PADE) inspection at Lupin’s global pharmacovigilance group. The inspection closed with no observations.

The inspection was conducted at Lupin’s global pharmacovigilance group based out of Mumbai from March 20 to March 24, 2023. The inspection included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Lupin’s marketed products worldwide.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

1615.85 20.95 (1.31%)
26-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1504.25
Dr. Reddys Lab 6263.70
Cipla 1406.25
Zydus Lifesciences 948.20
Lupin 1615.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.